This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisHoldingsRatingsShort InterestTrendsBuy This Stock About Range Cancer Therapeutics ETF (NASDAQ:CNCR) 30 days 90 days 365 days Advanced Chart Remove Ads Get CNCR alerts:Sign Up Key Stats Today's Range$11.63▼$11.8250-Day Range$27.45▼$32.2552-Week Range$8.96▼$16.27Volume1,757 shsAverage Volume6,159 shsMarket Capitalization$7.28 millionAssets Under Management$7.36 millionDividend Yield3.11%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF OverviewThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More… Remove Ads Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.57%0.56%0.53%0.53%Other Expenses0.00%0.30%0.49%0.43%0.52%Total Expense0.79%0.70%0.72%0.68%0.71%Fee Waiver0.00%-0.45%-0.50%-0.30%-0.55%Net Expense0.79%0.61%0.63%0.62%0.60% Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address CNCR ETF News HeadlinesTango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 23, 2024 | msn.comBuy Rating Affirmed for TScan Therapeutics Amid Positive Developments in TCR-T Cell Therapy SpaceOctober 12, 2024 | markets.businessinsider.comI’m prepared to put my reputation on the line…Brace Yourself for Jeff Bezos' "Amazon Helios" Amazon delivers 20 million packages a day... powers some of the most popular websites... delivers medication to half of the U.S. population... and even produces award-winning films and TV shows. But a Wall Street legend – twice featured on 60 Minutes – predicts that "Amazon Helios" will be bigger than all of those... COMBINED.April 2, 2025 | Stansberry Research (Ad)Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC SubpopulationSeptember 9, 2024 | seekingalpha.comRange Oncology Therapeutics Index ETF (CNCR)August 15, 2024 | finance.yahoo.comTango Therapeutics Shuts Early-Stage Cancer Study Due To Liver ToxicityMay 23, 2024 | msn.comSee More Headlines CNCR ETF - Frequently Asked Questions What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Range Cancer Therapeutics ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Cancer Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings76 Fund Statistics Assets Under Management$7.36 million Average Daily Volume$1,749.00 Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest6,800 shs Miscellaneous Outstanding Shares780,814Beta0.93 Creation Unit50,000 Creation Fee$150.00 10 Stocks Set to Soar in Spring 2025Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.Get This Free Report Top 10 CNCR HoldingsRecursion Pharmaceuticals (NASDAQ:RXRX)Holding Weight: 3.62%Precigen (NASDAQ:PGEN)Holding Weight: 3.38%Compass Therapeutics (NASDAQ:CMPX)Holding Weight: 2.70%SpringWorks Therapeutics (NASDAQ:SWTX)Holding Weight: 2.70%Exelixis (NASDAQ:EXEL)Holding Weight: 2.51%Genelux (NASDAQ:GNLX)Holding Weight: 2.51%Bristol-Myers Squibb (NYSE:BMY)Holding Weight: 2.22%Schrödinger (NASDAQ:SDGR)Holding Weight: 2.17%Ginkgo Bioworks (NYSE:DNA)Holding Weight: 2.10%Monte Rosa Therapeutics (NASDAQ:GLUE)Holding Weight: 2.10%Full Holdings Details This page (NASDAQ:CNCR) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.